149 related articles for article (PubMed ID: 34336552)
21. Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma.
Shen L; Qian C; Cao H; Wang Z; Luo T; Liang C
World J Surg Oncol; 2018 Dec; 16(1):235. PubMed ID: 30558624
[TBL] [Abstract][Full Text] [Related]
22. Significance of multifocality in papillary thyroid carcinoma.
Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
[TBL] [Abstract][Full Text] [Related]
23. Circular RNA circ_0008274 enhances the malignant progression of papillary thyroid carcinoma via modulating solute carrier family 7 member 11 by sponging miR-154-3p.
Ma J; Kan Z
Endocr J; 2021 May; 68(5):543-552. PubMed ID: 33473055
[TBL] [Abstract][Full Text] [Related]
24. Role of P53, E-cadherin and BRAF as predictors of regional nodal recurrence for papillary thyroid cancer.
Ali KM; Awny S; Ibrahim DA; Metwally IH; Hamdy O; Refky B; Abdallah A; Abdelwahab K
Ann Diagn Pathol; 2019 Jun; 40():59-65. PubMed ID: 31031216
[TBL] [Abstract][Full Text] [Related]
25. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
[TBL] [Abstract][Full Text] [Related]
26. Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.
Zhou C; Duan D; Liu S
Technol Cancer Res Treat; 2021; 20():15330338211027910. PubMed ID: 34191658
[TBL] [Abstract][Full Text] [Related]
27. Expression of leptin and its receptor in thyroid carcinoma: distinctive prognostic significance in different subtypes.
Fan YL; Li XQ
Clin Endocrinol (Oxf); 2015 Aug; 83(2):261-7. PubMed ID: 25158596
[TBL] [Abstract][Full Text] [Related]
28. An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
He HC; Kashat L; Kak I; Kunavisarut T; Gundelach R; Kim D; So AK; MacMillan C; Freeman JL; Ralhan R; Walfish PG
PLoS One; 2012; 7(9):e42893. PubMed ID: 23049733
[TBL] [Abstract][Full Text] [Related]
29. Implication of minimal extrathyroidal extension as a prognostic factor in papillary thyroid carcinoma.
Shin JH; Ha TK; Park HK; Ahn MS; Kim KH; Bae KB; Kim TH; Choi CS; Kim TK; Bae SK; Kim SH
Int J Surg; 2013; 11(9):944-7. PubMed ID: 23820062
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.
Siraj AK; Pratheeshkumar P; Parvathareddy SK; Bu R; Masoodi T; Iqbal K; Al-Rasheed M; Al-Dayel F; Al-Sobhi SS; Alzahrani AS; Al-Dawish M; Al-Kuraya KS
Eur J Cancer; 2019 Aug; 117():133-144. PubMed ID: 31280122
[TBL] [Abstract][Full Text] [Related]
31. Overall Survival of Papillary Thyroid Carcinoma Patients: A Single-Institution Long-Term Follow-Up of 5897 Patients.
Ito Y; Miyauchi A; Kihara M; Fukushima M; Higashiyama T; Miya A
World J Surg; 2018 Mar; 42(3):615-622. PubMed ID: 29349484
[TBL] [Abstract][Full Text] [Related]
32. Identification of a Signature Comprising 5 Soluble Carrier Family Genes to Predict the Recurrence of Papillary Thyroid Carcinoma.
Han R; Sun W; Zhang H
Technol Cancer Res Treat; 2021; 20():15330338211036314. PubMed ID: 34590520
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of serum lncRNA-ABHD11-AS1 as poor prognosis of patients with papillary thyroid carcinoma.
Hou S; Zhuang YY; Lin QY; Chen Z; Zhao HG; Zhang L; Lin CH
Exp Mol Pathol; 2021 Aug; 121():104658. PubMed ID: 34102210
[TBL] [Abstract][Full Text] [Related]
34. BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability.
Zhao M; Yang F; Sang C; Yan C; Wang Z
J Endocrinol Invest; 2021 Oct; 44(10):2165-2174. PubMed ID: 33543443
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.
Dettmer M; Perren A; Moch H; Komminoth P; Nikiforov YE; Nikiforova MN
Thyroid; 2013 Nov; 23(11):1383-9. PubMed ID: 23427895
[TBL] [Abstract][Full Text] [Related]
36. Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size.
Ito Y; Fukushima M; Kihara M; Takamura Y; Kobayashi K; Miya A; Miyauchi A
Endocr J; 2012; 59(6):457-64. PubMed ID: 22447137
[TBL] [Abstract][Full Text] [Related]
37. Expression of the membrane mucins MUC4 and MUC15, potential markers of malignancy and prognosis, in papillary thyroid carcinoma.
Nam KH; Noh TW; Chung SH; Lee SH; Lee MK; Hong SW; Chung WY; Lee EJ; Park CS
Thyroid; 2011 Jul; 21(7):745-50. PubMed ID: 21615302
[TBL] [Abstract][Full Text] [Related]
38. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of Forkhead box Q1 correlates with poor prognosis in papillary thyroid carcinoma.
Li Y; Wang HQ; Wang AC; Li YX; Ding SS; An XJ; Shi HY
Clin Endocrinol (Oxf); 2019 Feb; 90(2):334-342. PubMed ID: 30378716
[TBL] [Abstract][Full Text] [Related]
40. Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls.
Carr AA; Yen TWF; Ortiz DI; Hunt BC; Fareau G; Massey BL; Campbell BH; Doffek KL; Evans DB; Wang TS
Thyroid; 2018 Nov; 28(11):1462-1467. PubMed ID: 30215297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]